Features

Jocelyn Lafond – Theratechnologies

Biopharma lawyer mixes law and business in clinical trials

For Jocelyn Lafond, the best part of being an in-house counsel is not only helping Theratechnologies grow, but knowing that his work also helps patients. As a business partner, he directs his team to balance risks in activities such as research, development and the commercialization of the company’s products.

“Living in the business on a daily basis allows me that perspective,” he says. “When you’re outside counsel, you can’t give advice that’s as tailored.”

Jocelyn Lafond | Vice President, Legal Affairs, and Corporate Secretary | Theratechnologies

Jocelyn Lafond | Vice President, Legal Affairs, and Corporate Secretary | Theratechnologies

With Theratechnologies’s work being so complex, Lafond says it’s especially important to have a lawyer who comprehends what the business does and what it wants to do. The international biopharmaceutical company, headquartered in Montreal, Canada, focuses on oncology, HIV and non-alcoholic steatohepatitis, an advanced form of liver disease . It develops and commercializes therapeutic medicines in Canada, the U.S. and Europe.

Throughout its 28-year history, Theratechnologies has been a research and development company, then a commercial company, and now both. Lafond drafts and negotiates agreements, reviews licenses and protects intellectual property. He also supports the company as it goes through clinical trials.

“I’m able to provide a legal perspective as well as a business risk assessment of what we can do versus what we should do,” Lafond says. “It allows me to go beyond law and mix law with business.”

Outside assistance

While Lafond prefers being in-house counsel, he says partnering with outside counsel is essential in his work.

For example, Foley and Lardner, a firm with offices in Washington, D.C., helps Theratechnologies with intellectual property matters in the U.S. As the company develops new molecules and commercializes more of its drugs and makes them available as prescriptions, Lafond says it’s important to protect intellectual property and ensure competitors aren’t infringing in any way.

He also works closely with Jenner and Block, headquartered in Chicago, on corporate securities and labor law matters in the U.S. As Theratechnologies grows in the U.S. and hires employees with a wide array of expertise, Lafond needs to ensure that the company is compliant with all labor laws, he says.

Because laws vary in each U.S. state as well as in each European country the company operates in, he works with outside counsel to understand and follow the different regulations.

Clinical support

Lafond also helps the company markets its drugs compliantly, working closely with the marketing department. However, he doesn’t oversee compliance for the drugs—the regulatory team does that. He is involved in the research and development  that goes in to creating the drugs, though.

Jocelyn Lafond | Vice President, Legal Affairs, and Corporate Secretary | Theratechnologies

Theratechnologies is currently working on a couple of clinical trials. The company is in a phase one clinical trial in oncology for molecules it’s licensed, which Lafond says could be a new treatment option for various types of cancers. He’s been drafting, negotiating and reviewing the license and other legal documents associated with it and has helped negotiate the clinical site agreements.

The company is also in a phase three clinical trial for its own peptide, which holds similar promise, but those trials are on hold until a partner or additional financing can be secured. From a legal and regulatory standpoint, the trial is “ready to go,” Lafond says. When a partner or financing is secured, he’ll be involved in all the legal aspects surrounding the transaction.

“I like having a sense that I’m helpful to the organization and that people trust me,” he says. “I have a chance in this particular position to know exactly what is going on in the business, what the issues are and how I can help.”

Like what you do

The ways in which Lafond has been able to grow at Theratechnologies has made the work especially fulfilling, he says. Between his legal responsibilities, which he says are different day-to-day, and his board involvement as corporate secretary, he says he’s become a better, more well-rounded lawyer over the past 15 years.

He came to Theratechnologies from an international law firm in Montreal. He earned his law degree from the Université Laval in Quebec City and his master’s degree from the University of Toronto.

He was drawn to Theratechnologies because he wanted to be part of a decision-making team operating in an innovative field.

Jocelyn Lafond | Vice President, Legal Affairs, and Corporate Secretary | Theratechnologies

“I’ve really enjoyed the ever-changing dynamics of the business,” Lafond says. “It’s stimulating because you have to constantly adapt.”

He adds that he appreciates Theratechnologies’s embrace of change and its willingness to take risks. While his job is to assess and manage risk, he says it’s exciting to be at the forefront of new ideas and medicines.

“I’m doing what I do because I like it,” Lafond says. “I know, on a daily basis, that of course there will be things I don’t like as much, but overall, I fundamentally enjoy what I do and the growing complexity of all aspects of the pharma industry keeps me on my toes.”

View this feature in the Vanguard Winter I 2022 Edition here.

Published on: November 30, 2021

regions:

categories:

Showcase your feature on your website with a custom “As Featured in Vanguard” badge that links directly to your article!

Copy and paste this script into your page coding (ideally right before the closing tag) where you want to display our review banner.

Testimonials

It was a great honor to be featured in Vanguard Law. Working with every member of the team, from the initial interview with Erin Clark, through production with Victor Martins, writing the article with Taryn Plumb and creating the final content with Dave Gushee, was a true pleasure. Everyone was very professional, enthusiastic and supportive, and their creative approach and positive attitude clearly came through in the final product.
– Kevin C. Rakowski, Senior Vice President, Deputy General Counsel, Compliance with Radian Group Inc.
The piece highlighting my company, Bob Baker Enterprises, Inc., came out fabulous. Our company is in the new and used car sales and service industry. Everyone was great to work with and extremely professional. They produced a high-quality product and have provided expert assistance and guidance post-production of the article.
– Wade Poulson, General Counsel, Bob Baker Enterprises Inc.
I was honored to be the subject of an article. I enjoy reading Vanguard articles and seeing how other attorneys got to their positions and see their jobs. It's also interesting to see how different law firms partner with the subjects of the articles.
– Henry Marquard, in-house counsel, Stanley Consultants Inc.
As promised in advance, my feature in Vanguard has increased my visibility within the profession and prompted more than a few people I have not communicated with recently to reconnect. One of the Italian law firms I have used in the past is now in the process of interviewing me for an article on their website and tweeting out the feature story. Activity and the number of people connecting with me on LinkedIn has soared, which is great. The Vanguard writers and editorial staff were great to work with—highly professional and made the effort to make the experience both fun and rewarding (they were also respectful of the time pressures and demands all lawyers face). I was very pleased with the experience and the final outcome. Needless to say, I have been very pleased. All in all working with Vanguard has been a very positive experience which generated good publicity for both Shawcor and myself. My sincere thanks.
– Tim Hutzul, General Counsel, ShawCor Ltd.

LATEST EDITION

Fall I 2022

READ NOW

GET VANGUARD IN YOUR INBOX.

  • * We’ll never share your email or info with anyone.
  • This field is for validation purposes and should be left unchanged.